News | Womens Cardiovascular Health | January 06, 2021

Long-term Outcomes After Coronary Bypass Show Worse Outcomes for Women

Better outcomes seen in multiple vs. single coronary artery bypass grafts (CABG) in men and sex appears to play a role in mortality

A coronary artery bypass graft (CABG) procedure where blockages in the coronaries are bypassed using a blood vessel harvested from elsewhere in the body and connected to the vessel past the blockage to supply blood to the heart. A new study shows better outcomes seen in multiple vs. single coronary artery bypass grafts (CABG) in men and sex appears to play a role in mortality. Getty Images

A coronary artery bypass graft (CABG) procedure where blockages in the coronaries are bypassed using a blood vessel harvested from elsewhere in the body and connected to the vessel past the blockage to supply blood to the heart. A new study shows better outcomes seen in multiple vs. single coronary artery bypass grafts (CABG) in men and sex appears to play a role in mortality. Getty Images


January 6, 2020 — A new Weill Cornell Medicine found the risk of dying seven years after coronary artery bypass graft (CABG) surgery was significantly lower in men receiving multiple bypass grafts rather than single grafts. The study also looked at CABG in women and there was no apparent difference between single or multiple vessel bypass procedures, but overall women had a higher mortality rate. The study published online Dec. 23 in the Journal of the American Medical Association (JAMA) Cardiology.[1] 

Led by WCM cardiology expert Mario F.L. Gaudino, M.D., analyzed data from more than 63,402 patients in New York’s Cardiac Surgery Reporting System and New York’s Vital Statistics file who underwent CABG between Jan. 1, 2005, to Dec. 31, 2014. The findings raises important questions about why cardiovascular outcomes differ by sex and underscores the need for prospective clinical trials in women. 

In this statewide cohort study, at 7 years’ follow-up, outcomes with multiple arterial grafting were better among low-risk, but not high-risk, patients. Mortality at 7 years was lower among men, but not women, undergoing multiple arterial grafting.

“Previous evidence for women has been unclear as women typically represent only about 20 percent of patients who undergo coronary artery bypass procedures overall and less than 15 percent of clinical trial participants,” Gaudino explained.

The study suggests that women have a worse pre-operative risk profile than men. Multiple arterial grafting is associated with better outcomes among low-risk, but not high-risk, patients, and the risk cutoffs differ between sexes. These data highlight the need for new studies on the outcome of multiple arterial grafts in women.

Results of the study show patients (48,155 men [76%]; mean [SD] age, 69.9 [10.5] years) in the study, women had worse baseline characteristics than men for most of the explored variables. Propensity matching yielded a total of 9,512 male pairs and 1,860 female pairs. 

At 7 years of follow-up, mortality was lower among men who underwent multiple arterial grafting (adjusted hazard ratio, 0.80; 95% CI, 0.73-0.87) but not women who underwent multiple arterial grafting (adjusted hazard ratio, 0.99; 95% CI, 0.84-1.15). 

When stratified by the estimated risk of death, the use of multiple arterial grafts was associated with better survival and a lower rate of a major adverse cardiac event among low-risk, but not high-risk, patients of both sexes, and the risk cutoff was different for men and women.

Find more articles and videos on women's cardiovascular health

Reference:

1. Mario Gaudino, MD, MSCE; Zaza Samadashvili, MD; Irbaz Hameed, MD; et al. Differences in Long-term Outcomes After Coronary Artery Bypass Grafting Using Single vs Multiple Arterial Grafts and the Association With Sex. JAMA Cardiol. Published online Dec. 23, 2020. doi:10.1001/jamacardio.2020.6585.

 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now